Marshall Wace
KPTI icon

Marshall Wace’s Karyopharm Therapeutics KPTI Stock Holding History

Marshall Wace’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Hold
128,451
– – ﹤0.01% 2088
2026
Q1 		$715K Hold
128,451
– – ﹤0.01% 2296
2025
Q4 		$945K Hold
128,451
– – ﹤0.01% 1959
2025
Q3 		$840K Hold
128,451
– – ﹤0.01% 2015
2025
Q2 		$554K Hold
128,451
– – ﹤0.01% 2111
2025
Q1 		$480K Sell
128,451
-31,643
-20% -$270K ﹤0.01% 2091
2024
Q4 		$1.63M Buy
160,094
+21,279
+15% +$257K ﹤0.01% 1523
2024
Q3 		$1.73M Sell
138,815
-33,243
-19% -$413K ﹤0.01% 1424
2024
Q2 		$2.25M Sell
172,058
-982
-0.6% -$16.3K ﹤0.01% 1310
2024
Q1 		$3.92M Buy
173,040
+44,588
+35% +$782K 0.01% 1096
2023
Q4 		$1.66M Sell
128,452
-17,095
-12% -$230K ﹤0.01% 1300
2023
Q3 		$2.93M Sell
145,547
-17,386
-11% -$390K 0.01% 1063
2023
Q2 		$4.37M Buy
162,933
+30,606
+23% +$1.32M 0.01% 1082
2023
Q1 		$7.72M Sell
132,327
-15,021
-10% -$741K 0.02% 807
2022
Q4 		$7.51M Buy
147,348
+136,739
+1,289% +$9.48M 0.02% 963
2022
Q3 		$868K Buy
10,609
+9,076
+592% +$678K ﹤0.01% 2469
2022
Q2 		$103K Buy
+1,533
New +$141K ﹤0.01% 3275
2022
Q1 		– Sell
-600
Closed -$57K – 3692
2021
Q4 		$57K Buy
+600
New +$59.8K ﹤0.01% 3536
2021
Q1 		– Sell
-14,495
Closed -$3.37M – 2683
2020
Q4 		$3.37M Buy
14,495
+13,239
+1,054% +$3.07M 0.02% 720
2020
Q3 		$275K Buy
+1,256
New +$307K ﹤0.01% 1386
2020
Q1 		– Sell
-19,634
Closed -$5.64M – 1865
2019
Q4 		$5.64M Buy
+19,634
New +$4.26M 0.04% 488

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace's KPTI Position: Q2 2026 in Review

Marshall Wace held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 128,451 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

Marshall Wace first reported a position in KPTI in Q4 2019 and has held it in 21 quarters since. The position peaked at $7.72M in Q1 2023. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Marshall Wace held 128,451 shares of Karyopharm Therapeutics worth $1.25M as of Q2 2026.
  • Marshall Wace left its Karyopharm Therapeutics share count unchanged in Q2 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2088 holding.
  • Marshall Wace first reported a position in Karyopharm Therapeutics in Q4 2019 and has held it in 21 quarters since.
  • Marshall Wace's Karyopharm Therapeutics position peaked at $7.72M in Q1 2023.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.